The mission is remission: Health economic consequences of achieving full remission with antidepressant treatment for depression

International Journal of Clinical Practice

Volumn 60, Issue 7, 2006, Pages 791-798

  Sobocki, Patrik ^a,b   Ekman, M ^b   Agren H ^a,c   Runeson, B ^a   Jonsson B ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Antidepressant; Cost; Depression; Primary care; Quality of life; Remission; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OUTPATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SWEDEN;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; QUALITY OF LIFE; REMISSION INDUCTION; SICK LEAVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745077987     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00997.x     Document Type: Article

References (49)

1. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60 (Suppl. 22): 29-34.
2. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999; 60 (Suppl. 22): 7-11.
3. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness ? Am J Psychiatry 2000; 157: 1501-4.
4. Ramana R, Paykel ES, Cooper Z et al. Remission and relapse in major depression: A two-year prospective follow-up study. Psychol Med 1995; 25: 1161-70.
5. Thase ME, Simons AD, McGeary J et al. Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment. Am J Psychiatry 1992; 149: 1046-52.
6. de Groot M, Anderson R, Freedland KE et al. Association of depression and diabetes complications: A meta-analysis. Psychosom Med 2001; 63: 619-30.
7. Empana JP, Sykes DH, Luc G et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005; 111: 2299-305.
8. Everson SA, Roberts RE, Goldberg DE et al. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998; 158: 1133-8.
9. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819-25.
10. Gamma A, Angst J. Concurrent psychiatric comorbidity and multimorbidity in a community study: Gender differences and quality of life. Eur Arch Psychiatry Clin Neurosci 2001; 251 (Suppl. 2): II43-6.
11. Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1466-74.
12. Lustman PJ, Anderson RJ, Freedland KE et al. Depression and poor glycemic control: A meta-analytic review of the literature. Diabetes Care 2000; 23: 934-42.
13. Murphy JM, Monson RR, Olivier DC et al. Affective disorders and mortality. A general population study. Arch Gen Psychiatry 1987; 44: 473-80.
14. Penninx BW, Beekman AT, Honig A et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 221-7.
15. Penninx BW, Guralnik JM, Pahor M et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998; 90: 1888-93.
16. Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med 2002; 23: 51-61.
17. Vaccarino V, Kasl SV, Abramson J et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001; 38: 199-205.
18. Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59: 608-19.
19. Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 1995; 25: 1171-80.
20. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology 1998; 31: 5-14.
21. Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 1995; 25: 1171-80.
22. Simon GE, Revicki D, Heiligenstein J et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153-62.
23. Hays RD, Wells KB, Sherbourne CD et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995; 52: 11-9.
24. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry 1999; 56: 897-904.
25. The EuroQol Group. EuroQol -a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199 -208.
26. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559-75.
27. Sapin C, Fantino B, Nowicki ML et al. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004; 2: 20.
28. Saarijarvi S, Salminen JK, Toikka T et al. Health-related quality of life among patients with major depression. Nord J Psychiatry 2002; 56: 261-4.
29. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
30. Sobocki P, Ekman M, Ågren H et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health (in press).
31. Sobocki P, Ekman M, Ågren H et al. Resource-use and costs associated with patients treated for depression in primary care. Eur J Health Econ (in press).
32. Wackerly DD, Mendenhall W, Schaeffer RL. Mathematical Statistics with Applications, 5th edn. Belmont: Duxbury Press, 1996.
33. Briggs A, Gray A. Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 1999; 3: 35-60.
34. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993.
35. Kleinbaum D, Kupper L, Muller K et al. Applied Regression Analysis and Multivariable Methods. Pacific Grove, CA: Duxbury Press, 1998.
36. Collett D. Modelling Survival Data in Medical Research. Boca Raton, Florida: Chapman&Hall/CRC Press, 2003.
37. Simon GE, Chisholm D, Treglia M et al. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002; 24: 328-35.
38. Simon GE, Katon W, Rutter C et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med 1998; 28: 693-701.
39. VonKorff M, Ormel J, Katon W et al. Disability and depression among high utilizers of health care. Arch Gen Psychiatry 1992: 91-100.
40. Coulehan JL, Schulberg HC, Block MR et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Intern Med 1997; 157: 1113-20.
41. Simon GE, Barber C, Birnbaum HG et al. Depression and work productivity: The comparative costs of treatment versus nontreatment. J Occup Environ Med 2001; 43: 2-9.
42. Peveler R, Kendrick T, Buxton M et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess 2005; 9: 1-134, iii.
43. Revicki DA, Turner R, Brown R et al. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Qual Life Res 1992; 1: 257-66.
44. Schoenbaum M, Sherbourne C, Wells K. Gender patterns in cost effectiveness of quality improvement for depression: Results of a randomized, controlled trial. J Affect Disord 2005; 87: 319-25.
45. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications. J Affect Disord 1998; 48: 25-36.
46. Mintz J, Mintz LI, Arruda MJ et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761-8.
47. Simon G, Ormel J, VonKorff M et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152: 352-7.
48. Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97-108.
49. Kessing LV, Hansen MG, Andersen PK et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders -a life-long perspective. Acta Psychiatr Scand 2004; 109: 339-44.